<DOC>
	<DOCNO>NCT01814098</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety long term escitalopram treatment participant Major Depressive Disorder ( MDD ) associate anxiety symptom .</brief_summary>
	<brief_title>An Efficacy Safety Study Escitalopram Long-Term Treatment Major Depressive Disorder With Associated Anxiety Symptoms</brief_title>
	<detailed_description>This open-label ( people know identity intervention ) , single arm , prospective ( study follow participant forward time ) , post-marketing , multi-center ( one hospital medical school team work medical research study ) study evaluate efficacy safety escitalopram participant MDD associate anxiety symptom . The duration study 24 week start dose escitalopram 10 milligram per day ( mg/day ) . The dose flexibly adjust ( maximum 20 mg/day ) 2 week treatment depend Investigator 's discretion . The study consist 9 visit : Baseline , Week 1 , 2 , 4 , 8 , 12 , 16 , 20 24 . Assessments efficacy safety perform visit . The primary efficacy evaluation do Montgomery-Asbery Depression Rating Scale ( MADRS ) Hamilton Anxiety Scale ( HAM-A ) . Participant 's safety also monitor throughout study .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Citalopram</mesh_term>
	<mesh_term>Dexetimide</mesh_term>
	<criteria>Participant must willing able give write informed consent Participant currently suffer Major Depressive Disorder ( MDD ) anxious symptom include participant first MDD episode , relapse participant new episode Participant minimum score baseline 22 MontgomeryAsbery Depression Rating Scale ( MADRS ) minimum score baseline 14 Hamilton Anxiety Rating ( HAMA ) scale Female participant must surgically sterile , practice effective method birth control entry throughout study Participant continuously take psychoactive substance , antidepressant , anxiolytic , monoamine oxidase inhibitor ( MAOIs ) , psychoactive herbal remedy , lithium , electroconvulsive therapy ( ECT ) carbamazepine past 2 week baseline visit Participants MDD , require treatment systematically within past 2 month baseline Participants contraindication escitalopram Participant primary comorbid diagnose schizophrenia ( psychiatric disorder symptom emotional instability , detachment reality , often delusions hallucination [ imagine thing ] , withdrawal self ) , schizoaffective disorder ( mixed psychiatric disorder relate complex psychotic state feature schizophrenia mood disorder bipolar disorder ) , bipolar disorder , dementia ( mental decline ) Participant significant risk suicide clinical assessment make serious suicide attempt within past 6month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>Depressive Disorder , Major</keyword>
	<keyword>Escitalopram</keyword>
	<keyword>Lexapro</keyword>
</DOC>